Evaluating the effectiveness of a new RSV vaccine for mothers and infants
Official title: Real-World Effectiveness of Maternal RSV Vaccination
Funded at University of San Francisco · NIH-11120644 · Data updated 2026-11-12
This study is looking at how well a new RSV vaccine given to pregnant women works to protect their babies from RSV infections, especially when combined with other treatments, so that doctors and parents can make the best choices for keeping infants healthy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $249,276 |
| NIH project number | 1R21AI191038-01 |
| Project ID | NIH-11120644 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include pregnant women who are between 32 and 36 weeks of gestation and their infants.
✕Less likely to help
Patients who are not pregnant or whose infants are older than 8 months may not benefit from this research.
What this research studies
This research investigates the real-world effectiveness of a newly licensed RSV vaccine administered to pregnant women. The study aims to understand how well the vaccine prevents respiratory syncytial virus (RSV) infections in infants, particularly in the context of other treatments like monoclonal antibodies. By analyzing data from various settings, the research will assess the vaccine's performance outside of clinical trials, considering factors such as the timing of administration and concurrent treatments. This information will help inform healthcare providers and parents about the best preventive measures against RSV.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of RSV-related illnesses and deaths in infants.
How similar studies have gone: Previous research has shown promising results with similar vaccine approaches, indicating potential for success in this area.
Where this research is happening
-
University of San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Regan, Annette Karena — University of San Francisco
- Study coordinator: Regan, Annette Karena
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Respiratory pathogen–specific T cell signatures after vaccination, infection, and treatment
A research effort to map how immune T cells respond to respiratory infections and vaccines, with potential to guide better vaccines and treatments for conditions like covid-19 and pertussis.
-
Malaria vaccine and infection: how the body’s early and later immune responses relate to protection
Researchers are studying how people’s immune systems respond to the malaria pre-erythrocytic stage, whether after vaccination or infection, to identify which responses are linked to protection.
-
Spatially responsive mass vaccination for urban rabies
A new plan uses data and maps to place vaccination sites where they’re most needed in cities, aiming to boost rabies vaccination for both people and dogs.
-
Spatially responsive mass vaccination for urban rabies
A project tests smarter placement of vaccination sites to increase mass canine rabies vaccination in cities.
-
Vaccine failure after Covid-19 vaccination in older adults
This project follows vaccinated older adults to understand who among them still gets Covid-19 and what factors make those outcomes worse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.